Study details
Enrolling now
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
Natalie Denburg
NCT IDNCT03954899ClinicalTrials.gov data as of Apr 2026
Target enrollment
230
Study length
about 6.1 years
Ages
56–85
Locations
1 site in IA
About this study
This trial is testing whether a treatment of 5mg melatonin improves Alzheimer's disease biomarkers and cognitive function in older adults. Participants will have blood draws to measure biomarkers, and their cognitive function will be assessed with tests. The lumbar puncture procedures for this clinical trial have been eliminated.
Based on ClinicalTrials.gov records.
What participants do
- 1.Melatonin
- 2.Placebo
Drugmelatonin
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
melatonin (Hormone supplement; regulates sleep-wake cycle)
Drug routes
oral (Disintegrating Oral Tablet)
Endpoints
Secondary: Sleep Efficiency
Body systems
Neurology